Benitec Biopharma (BNTC) Other Accumulated Expenses (2019 - 2025)

Benitec Biopharma has reported Other Accumulated Expenses for 7 years, with the latest figure at $62000.0 in Q4 2025.

• Quarterly Other Accumulated Expenses fell 32.61% year-over-year to $62000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $62000.0 (down 32.61% YoY) and the FY2025 annual result came in at $67000.0, down 51.45% from the prior year.
• Other Accumulated Expenses declined to $62000.0 in Q4 2025 per BNTC's latest filing, from $147000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $223000.0 in Q4 2021 and troughed at $36000.0 in Q1 2023.
• A 5-year average of $96050.0 and a median of $76500.0 in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses slumped 81.61% in 2022, then soared 149.15% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $223000.0 in 2021, then plunged by 81.61% to $41000.0 in 2022, then jumped by 80.49% to $74000.0 in 2023, then increased by 24.32% to $92000.0 in 2024, then plunged by 32.61% to $62000.0 in 2025.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $62000.0, $147000.0, and $67000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.